Fosfomycin: Mechanism and resistance

Cold Spring Harbor Perspectives in Medicine

Volumn 7, Issue 2, 2017, Pages

  Silver, Lynn L ^a  

^a LL Silver Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG MECHANISM; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PARENTERAL DRUG ADMINISTRATION; TREATMENT INDICATION; UNITED STATES; URINARY TRACT INFECTION; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 85011581637     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025262     Document Type: Article

References (58)

1. Alper MD, Ames BN. 1978. Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: Positive selection of Salmonella typhimurium cya and crp mutants. J Bacteriol 133: 149–157.
2. Blake KL, O’Neill AJ, Mengin-Lecreulx D, Henderson PJ, Bostock JM, Dunsmore CJ, Simmons KJ, Fishwick CW, Leeds JA, Chopra I. 2009. The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Mol Microbiol 72: 335–343.
3. Brown ED, Marquardt JL, Lee JP, Walsh CT, Anderson KS. 1994. Detection and characterization of a phospholactoyl-enzyme adduct in the reaction catalyzed by UDPN-acetylglucosamine enolpyruvoyl transferase, MurZ. Biochemistry 33: 10638–10645.
4. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J. 2009. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol 191: 6968–6974.
5. Castañeda-García A, Blázquez J, Rodríguez-Rojas A. 2013. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. Antibiotics 2: 217–236.
6. Couce A, Briales A, Rodríguez-Rojas A, Costas C, Pascual A, Blázquez J. 2012. Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost. Antimicrob Agents Chemother 56: 2767–2769.
7. De Groote VN, Fauvart M, Kint CI, Verstraeten N, Jans A, Cornelis P, Michiels J. 2011. Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance. J Med Microbiol 60: 329–336.
8. De Smet KAL, Kempsell KE, Gallagher A, Duncan K, Young DB. 1999. Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis. Microbiology 145: 3177–3184.
9. Du W, Brown JR, Sylvester DR, Huang J, Chalker AF, So CY, Holmes DJ, Payne DJ, Wallis NG. 2000. Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in Gram-positive bacteria. J Bacteriol 182: 4146–4152.
10. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, Jacobs MR, Bonomo RA. 2010. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 54: 526–529.
11. Eschenburg S, Priestman M, Schonbrunn E. 2005. Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem 280: 3757–3763.
12. European Committee on Antimicrobial Susceptibility Testing. 2016. Breakpoint tables for interpretation of MICs and zone diameters. Version 6. www.eucast.org/clinical_breakpoints.
13. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. 2008. Fosfomycin: Use beyond urinary tract and gastrointestinal infections. Clin Inf Dis 46: 1069–1077.
14. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. 2009. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gramnegative bacilli: A systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 34: 111–120.
15. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. 2010a. Fosfomycin for the treatment of multidrugresistant, including extended-spectrum b-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Inf Dis 10: 43–50.
16. Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S. 2010b. Fosfomycin versus other antibiotics for the treatment of cystitis: A meta-analysis of randomized controlled trials. J Antimicrob Chemother 65: 1862–1877.
17. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. 2016. Fosfomycin. Clin Microbiol Rev 29: 321–347.
18. Gadebusch HH, Stapley EO, Zimmerman SB. 1992. The discovery of cell wall active antibacterial antibiotics. Crit Rev Biotechnol 12: 225–243.
19. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, et al. 1969. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 166: 122–123.
20. Hickman RA, Hughes D, Cars T, Malmberg C, Cars O. 2013. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Clin Microbiol Inf 20: O267–O273.
21. Jiang Y, Shen P, Wei Z, Liu L, He F, Shi K, Wang Y, Wang H, Yu Y. 2015. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents 45: 66–70.
22. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. 1974. The mechanism of action of fosfomycin (phosphonomycin). Ann NYAcad Sci 235: 364–386.
23. Kahlmeter G. 2000. The ECO†SENS Project: A prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens—Interim report. J Antimicrob Chemother 46: 15–22.
24. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. 2012. Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67: 255–268.
25. Katayama N, Tsubotani S, Nozaki Y, Harada S, Ono H. 1990. Fosfadecin and fosfocytocin, new nucleotide antibiotics produced by bacteria. J Antibiot (Tokyo) 43: 238–246.
26. Kedar GC, Brown-Driver V, Reyes DR, Hilgers MT, Stidham MA, Shaw KJ, Finn J, Haselbeck RJ. 2008. Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis. Antimicrob Agents Chemother 52: 2009–2013.
27. Kim DH, Lees WJ, Kempsell KE, Lane WS, Duncan K, Walsh CT. 1996. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry 35: 4923–4928.
28. Kim SY, Ju K-S, Metcalf WW, Evans BS, Kuzuyama T, van der Donk WA. 2012. Different biosynthetic pathways to fosfomycin in Pseudomonas syringae and Streptomyces species. Antimicrob Agents Chemother 56: 4175–4183.
29. Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, Asai K, Ashikaga S, Aymerich S, Bessieres P. 2003. Essential Bacillus subtilis genes. ProcNatl Acad Sci 100: 4678–4683.
30. Kock H, Gerth U, Hecker M. 2004. Mur AA, catalysing the first committed step in peptidoglycan biosynthesis, is a target of Clp-dependent proteolysis in Bacillus subtilis. Mol Microbiol 51: 1087–1102.
31. Kuzuyama T, Kobayashi S, O’Hara K, Hidaka T, Seto H. 1996. Fosfomycin monophosphate and fosfomycin diphosphate, two inactivated fosfomycin derivatives formed by gene products of fomA and fomB from a fosfomycin producing organism Streptomyces wedmorensis. J Antibiot (Tokyo) 49: 502–504.
32. Lemieux MJ, Huang Y, Wang DN. 2004. Glycerol-3-phosphate transporter of Escherichia coli: Structure, function and regulation. Res Microbiol 155: 623–629.
33. Li Y, Zheng B, Li Y, Zhu S, Xue F, Liu J. 2015. Antimicrobial susceptibility and molecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China. PLoS ONE 10: e0135269.
34. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. 2003. In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 22: 53–59.
35. Marquardt JL, Brown ED, Lane WS, Haley TM, Ichikawa Y, Wong CH, Walsh CT. 1994. Kinetics, stoichiometry, and Identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry 33: 10646–10651.
36. Nikolaidis I, Favini-Stabile S, Dessen A. 2014. Resistance to antibiotics targeted to the bacterial cell wall. Protein Sci 23: 243–259.
37. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 47: 2850–2858.
38. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martinez-Ruiz R, Perez-Vazquez M, Alcaraz M, Garcia-Cobos S, Campos J. 2009. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 64: 712–717.
39. Performance Standards for Antimicrobial Susceptibility Testing. 2012. 22nd informational supplement M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
40. Rodríguez-Rojas A, Couce A, Blázquez J. 2010a. Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. Antimicrob Agents Chemother 54: 4948–4949.
41. Rodríguez-Rojas A, Maciá MD, Couce A, Gómez C, Castañeda-García A, Oliver A, Blázquez J. 2010b. Assessing the emergence of resistance: The absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS ONE 5: e10193.
42. Sato N, Kawamura K, Nakane K, Wachino JI, Arakawa Y. 2013. First detection of fosfomycin resistance gene fosA3 in CTX-M-producing Escherichia coli isolates from healthy individuals in Japan. Microb Drug Res 19: 477–482.
43. Shoji J, Kato T, Hinoo H, Hattori T, Hirooka K, Matsumoto K, Tanimoto T, Kondo E. 1986. Production of fosfomycin (phosphonomycin) by Pseudomonas syringae. J Antibiot (Tokyo) 39: 1011–1012.
44. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. 1996. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 4: 1465–1474.
45. Suárez JE, Mendoza MC. 1991. Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother 35: 791–795.
46. Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S, Muratani T, Matsumoto T, Nakahama C, Tomono K. 2010. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 35: 333–337.
47. Thompson MK, Keithly ME, Goodman MC, Hammer ND, Cook PD, Jagessar KL, Harp J, Skaar EP, Armstrong RN. 2014. Structure and function of the genomically encoded fosfomycin resistance enzyme, FosB, from Staphylococcus aureus. Biochemistry 53: 755–765.
48. Tsuruoka T, Miyata A, Yamada Y. 1978. Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K-12. J Antibiot (Tokyo) 31: 192–201.
49. VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG. 2015. Exploration of the pharmacokinetic–pharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model. Antimicrob Agents Chemother 59: 7170–7177.
50. Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ. 2015. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 70: 3042–3050.
51. Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ. 2016. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother doi: 10.1093/jac/dkw115.
52. Wanke C, Amrhein N. 1993. Evidence that the reaction of the UDP-N-acetylglucosamine 1-carboxyvinyltransferase proceeds through the O-phosphothioketal of pyruvic acid bound to Cys115 of the enzyme. Eur J Biochem 218: 861–870.
53. Winkler HH. 1973. Distribution of an inducible hexosephosphate transport system among various bacteria. J Bacteriol 116: 1079–1081.
54. Wu HC, Venkateswaran PS. 1974. Fosfomycin-resistant mutant of Escherichia coli. Ann NY Acad Sci 235: 587–592.
55. Zavante Therapeutics. 2016. Zavante initiates the ZEUS study for ZTI-01 for the treatment of complicated urinary tract infections, Zavante Therapeutics, Inc., www.zavante.com/news/zavante-initiates-the-zeus-studyfor-zti-01-for-the-treatment-of-complicated-urinary-tractinfections.
56. Zhu JY, Yang Y, Han H, Betzi S, Olesen SH, Marsilio F, Schönbrunn E. 2012. Functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA). J Biol Chem 287: 12657–12667.
57. Zilhao R, Courvalin P. 1990.Nucleotide sequence of the fosB gene conferring fosfomycin resistance in Staphylococcus epidermidis. FEMS Microbiol Lett 68: 267–272.
58. Zimmerman S, Stapley E, Wallick H, Baldwin R. 1969. Phosphonomycin. IV: Susceptibility testing method and survey. Antimicrob Agents Chemother (Bethesda) 9: 303–309.